The use of generative artificial intelligence (AI) in clinical trial recruitment is rapidly changing how participants are identified, engaged, and enrolled. While the technology promises efficiency and broader reach, it also raises urgent ethical concerns. First, algorithmic bias in recruitment systems may reproduce or deepen health disparities, threatening efforts to build representative and inclusive clinical studies. Second, reliance on AI-generated patient materials complicates informed consent and transparency, since tailored outputs can obscure critical risks, oversimplify complex medical information, or frame participation in ways that undermine trust. Third, the integration of AI into recruitment workflows necessitates enhanced frameworks for accountability and responsible governance. Unlike traditional recruitment processes, generative AI involves layers of opacity, raising difficult questions about responsibility for errors, bias, and participant harm. Without strong regulatory oversight, the rapid adoption of AI-driven tools risks undermining participant protections and public trust in clinical research.
 
Kalina Kamenova PhD is Founder and Research Director of Canadian Institute For Genomics And Society | Toronto. Her work integrates bioethics, science policy, and public engagement strategies to shape evidence-based decisions in health and biomedical innovation, including genomics, precision medicine, stem cell and regenerative therapies, and artificial intelligence (AI) in healthcare. As Founder and Research Director of the Canadian Institute for Genomics and Society (Genomics4S), I have advanced participatory research, ethical governance, and policy innovation in emerging biotechnologies. Partnering with leading researchers, scientists, policymakers, and industry stakeholders, I have enabled strategic collaboration on initiatives that navigate the ethical and societal dimensions of biomedical innovation. With prior leadership experience at Loyalist College’s Applied Research and Innovation Office and University of Alberta’s Centre for Public Involvement, I have also contributed to fostering cross-sectoral innovation through applied research, policy development, and strategic partnerships. My executive and management expertise spans research administration, grant development, research ethics, team-building, and stakeholder engagement. I am driven by a commitment to responsible research and innovation, ensuring inclusive public discourse around transformative scientific advancements.

Other Posts

Due to the rise of AI chatbots, many people have turned to AI for medical advice or help. This article explains the variety of reasons why people might turn to AI, from quicker answers to [...]

In America, the responsibility of caring for elderly parents is both an investment of time and money, often from their adult children. However, in this article, the author explores the dynamic between parents and children [...]

Scientists are continuing to explore the use of CRISPR gene-editing technology in human embryos to prevent the transmission of inherited genetic diseases. While the research demonstrates the potential to reduce the burden of serious hereditary [...]

A growing Ebola outbreak in Uganda has prompted the Trump administration to reconsider how the United States coordinates its global response. As cases continue to rise, administration officials have discussed appointing a dedicated coordinator while [...]

The new HIV prevention drug lenacapavir is beginning to reach communities in Zambia, offering new hope in the global fight against HIV. Administered just twice a year, the injectable medication has demonstrated near-complete effectiveness in [...]

A new study published in the New England Journal of Medicine found that bepirovirsen, an experimental hepatitis B treatment, achieved a functional cure in about 1 in 5 patients with chronic hepatitis B after a [...]